Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Although gastrointestinal stromal tumors (GISTs) harboring activating KIT or platelet-derived growth factor receptor A ( PDGFRA ) mutations respond to treatment with targeted KIT/PDGFRA inhibitors such as imatinib mesylate, these treatments are rarely curative. Most often, a sizeable tumor cell subpopulation survives and remains quiescent for years, eventually resulting in acquired resistance and treatment failure. Here, we report that imatinib induces autophagy as a survival pathway in quiescent GIST cells. Inhibiting autophagy, using RNAi-mediated silencing of autophagy regulators (ATGs) or antimalarial lysosomotrophic agents, promotes the death of GIST cells both in vitro and in vivo. Thus, combining imatinib with autophagy inhibition represents a potentially valuable strategy to promote GIST cytotoxicity and to diminish both cellular quiescence and acquired resistance in GIST patients.